PercAssist

Perc Assist

Medical Devices, 2374 Walsh Ave, Santa Clara, California, 95051, United States, 1-10 Employees

percassist-corp.com

  • LinkedIn

Who is PERCASSIST

PercAssist technology is designed for hemodynamic support and cardiac recovery with simplicity, performance, and ease of use in mind for the patient and the clinician. The PercAssist proc...

Read More

map
  • 2374 Walsh Ave, Santa Clara, California, 95051, United States Headquarters: 2374 Walsh Ave, Santa Clara, California, 95051, United States
  • 2019 Date Founded: 2019
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Medical Devices

SIC SIC Code: 3841 | NAICS Code: 339112 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from PERCASSIST

PercAssist Org Chart and Mapping

Employees

Thi-Vu Huynh

Staff Research and Development Engineer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding PercAssist

Answer: PercAssist's headquarters are located at 2374 Walsh Ave, Santa Clara, California, 95051, United States

Answer: PercAssist's official website is https://percassist-corp.com

Answer: PercAssist's revenue is Under $1 Million

Answer: PercAssist's SIC: 3841

Answer: PercAssist's NAICS: 339112

Answer: PercAssist has 1-10 employees

Answer: PercAssist is in Medical Devices

Answer: PercAssist contact info: Phone number: Website: https://percassist-corp.com

Answer: PercAssist technology is designed for hemodynamic support and cardiac recovery with simplicity, performance, and ease of use in mind for the patient and the clinician. The PercAssist procedure is designed using a minimally invasive technique performed in the catheterization or hybrid lab. Proprietary ECG and implant technology applies ventricular compression synchronized with the patients natural heart rhythm. The implant does not reside in the bloodstream, reducing the possibility of anticoagulation therapy and the minimally invasive nature of the procedure is expected to shorten patient recovery time. Initial use is anticipated in emergent conditions such as cardiogenic shock and severe acute decompensated heart failure. Future use is anticipated in longer-term support of advanced heart failure patients including bridge to transplant or destination therapy. Caution: The PercAssist technology is under development and is for investigational use only. Not approved by FDA and not available for commercial distribution in the United States or any other market.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access